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In vitro exploration of ACAT contributions to lipid droplet
formation during adipogenesis
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Department of Food Science* and Purdue Center for Cancer Research,§ Purdue University, West Lafayette,
IN 47907; and Department of Biomedical Engineering,† Department of Electrical and Computer
Engineering, Boston University, Boston, MA 02215
ORCID ID: 0000-0002-1124-572X (K-H.K.)

Abstract As adipose tissue is the major cholesterol storage
organ and most of the intracellular cholesterol is distributed
to lipid droplets (LDs), cholesterol homeostasis may have a
role in the regulation of adipocyte size and function. ACATs
catalyze the formation of cholesteryl ester (CE) from free
cholesterol to modulate the cholesterol balance. Despite the
well-documented role of ACATs in hypercholesterolemia,
their role in LD development during adipogenesis remains
elusive. Here, we identify ACATs as regulators of de novo lipogenesis and LD formation in murine 3T3-L1 adipocytes.
Pharmacological inhibition of ACAT activity suppressed intracellular cholesterol and CE levels, and reduced expression of genes involved in cholesterol uptake and efflux.
ACAT inhibition resulted in decreased de novo lipogenesis,
as demonstrated by reduced maturation of SREBP1 and
SREBP1-downstream lipogenic gene expression. Consistent
with this observation, knockdown of either ACAT isoform
reduced total adipocyte lipid content by approximately
40%. These results demonstrate that ACATs are required
for storage ability of lipids and cholesterol in adipocytes.—
Zhu, Y., C-Y. Chen, J. Li, J-X. Cheng, M. Jang, and K-H. Kim.
In vitro exploration of ACAT contributions to lipid droplet
formation during adipogenesis. J. Lipid Res. 2018. 59:
820–829.
Supplementary key words adipocytes • avasimibe • cholesterol metabolism • fatty acid synthesis • triglycerides • acyl-CoA:cholesterol
acyltransferase

Adipose tissue is the primary depot for energy storage in
a form of triglyceride (TG) within the body. Stored TG is
then hydrolyzed to FAs in adipocytes by lipolysis during energy deficiency. Adipocytes are also the primary location
for the deposition of unesterified free cholesterol (FC),
mostly found in the cholesterol-rich endoplasmic reticulum (ER)-like surface layer of lipid droplets (LDs) as well as
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plasma membrane (1, 2). Several studies report a positive
correlation between intracellular cholesterol level and TG
content in adipocytes (1, 3–5). Indeed, cholesterol content
in adipocytes appears to be associated with human obesity,
as obese humans are reported to store 33–50% of body
cholesterol in adipose tissue, while lean humans have about
25% (5). Conversely, altered cholesterol homeostasis results in impairment of systemic energy balance. For example, CD36-deficient mice with a defect in cholesterol uptake
are resistant to high-fat diet-induced adipose tissue mass
gain and ectopic hepatic lipid accumulation (6). In addition, mice with Niemann-Pick type C1 deficiency were susceptible to high-fat diet-induced weight gain (7).
The majority (>90%) of adipocyte cholesterol is found
in the FC form and cholesteryl ester (CE) synthesis has
been reported to be significantly low (4). Although intracellular FC is primarily derived from the dietary sources in
adipocytes (4, 8), the synthesis of CE is catalyzed by ER resident ACATs/sterol O-acyltransferases (SOATs) (9). ACAT1
is ubiquitously expressed in different tissues to maintain
cholesterol homeostasis, whereas ACAT2 is mainly expressed in the liver and intestine. The synthesized CE is
then incorporated mostly into the lipid core of very low
density lipoprotein, chylomicrons, and/or TG-rich LDs
(10). Accumulated evidence suggests an important physiological function of ACATs in hypercholesterolemia and
atherosclerosis. ACAT1-deficient mice or wild-type mice
with transplanted ACAT1/ bone marrow cells exhibit
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severe atherosclerosis (11, 12), while mice with myeloidspecific ACAT1 knockout are protected from atherosclerosis progression (13). Moreover, ACAT2-deficient mice are
protected against diet-induced hypercholesterolemia due
to a loss of cholesterol esterification activity in the intestine
and liver (14). In addition, ACATs appear to play a key role
in various diseases, such as cancer (15) and Alzheimer’s
disease (16, 17). Despite this significant physiological importance of ACATs, their role in lipid metabolism in adipose tissue is still poorly understood.
Reportedly, the sterol synthesis pathway appears to play
an important role in TG synthesis and LD formation in
non-adipose tissue. For example, yeast mutants lacking
both Lro1 (the yeast ortholog of mammalian LCAT)
and Dga1 [the yeast ortholog of mammalian acyl-CoA:
diacylglycerol acyltransferase (DGAT)2] are deficient in
TG, but still maintain sterol ester-enriched LDs (18, 19).
However, additional deletion of Are1 and Are2, the genes
encoding sterol acyltransferases, in Lro1Dga1 yeast mutants abolishes LDs, indicating a key role of the sterol ester
biosynthetic pathways in the maturation of LDs in yeast
(19–21). Moreover, several studies demonstrate a potential
role of cholesterol metabolism in adipocyte lipogenesis:
i) genes involved in cholesterol metabolism and accumulation of FC and CE are differentially expressed during adipogenesis (22, 23); ii) altered de novo cholesterol biosynthesis
by statin treatment suppresses lipogenesis in adipocytes
(24, 25); and iii) perturbation of cholesterol export in adipocytes inhibits lipogenesis and adipocyte lipid storage,
lowers adiposity, and increases systemic energy expenditure in vivo (26). Accordingly, we hypothesized that ACATregulated CE synthesis and accumulation modulates
synthesis and storage of TG in LDs in adipocytes. Here, we
show that ACATs are required for de novo lipogenesis and
LD formation in adipocytes.

MATERIALS AND METHODS
Reagents
Insulin, dexamethasone, 3-isobutyl-1-methylxanthine, Oil Red
O (ORO), Polybrene, free glycerol reagent (#F6428), glycerol
standard solution (#G7793), TG reagent (#T2449), and avasimibe
(AVA) (>98% of purity) were purchased from Sigma-Aldrich (St.
Louis, MO). FCS and FBS were purchased from PAA (Dartmouth,
MA). DMEM, penicillin/streptomycin, and sodium pyruvate were
from VWR (Radnor, PA). TRIzol® reagent, SuperScriptII, and
Lipofectamine 2000 were from Invitrogen (Carlsbad, CA). The
3-(4,5-dimethyl-thiazol-yl-2)-2,5-diphenyl tetrazolium bromide
(MTT) was purchased from Alfa Aesar (Ward Hill, MA). The protein assay kit and iTaq™ Universal SYBR® Green Supermix
were from Bio-Rad Laboratories (Hercules, CA). The 25-[N-[(7nitro-2-1,3-benzoxadiazol-4-yl)methyl]amino]-27-norcholesterol
(25-NBD-chol) (#810250p) was purchased from Avanti Polar
Lipids (Alabaster, AL). Antibodies against SREBP1 (#sc8984) and
-actin and secondary HRP-conjugated mouse antibody were purchased from Santa Cruz Biotechnology (Dallas, TX). Secondary
HRP-conjugated rabbit antibody was from the Jackson Laboratory
(Bar Harbor, ME). Deuterium-glucose (1,2,3,4,5,6,6-D7, D-glucose,
#DLM-2062) was from Cambridge Isotope Laboratories (Tewksbury,

MA). The cholesterol assay kit (#K603-100) was from BioVision
(Milpitas, CA).

Cell culture and treatment conditions
The 3T3-L1 murine preadipocytes purchased from American
Type Culture Collection (Manassas, VA) were cultured and differentiated as described elsewhere (27, 28). The 3T3-L1 preadipocytes were maintained in 10% (v/v) FCS-DMEM with 100 U/ml
penicillin/streptomycin and 0.11 g/l sodium pyruvate at 37°C
with 5% CO2. After 2 days of postconfluency (designated as day
0), cells were differentiated with DMEM supplemented with 10%
FBS and an adipogenic cocktail containing 5 M dexamethasone,
0.5 mM 3-isobutyl-1-methyl-xanthine, and 167 nM insulin for 2
days (designated as days 0–2). Then, cells were maintained in
10% FBS-DMEM containing 167 nM insulin on days 2–4, followed
by culturing in 10% FBS-DMEM. On day 6 or later, mature adipocytes were fixed with 3.7% paraformaldehyde and stained with
ORO, as described previously (27). AVA was dissolved in DMSO
and added to the cell culture medium such that the final DMSO
concentration was less than or equal to 0.1% (v/v).

Cell viability assay
An MTT assay was performed to evaluate the effect of AVA
(0–20 M) on cell viability. The 3T3-L1 adipocytes differentiated
in a 24-well plate for 6 days were treated with the indicated AVA
concentrations for 48 h. The MTT solution (0.5 mg/ml) was then
applied to the cells for 1 h at 37°C with 5% CO2. Precipitated
formazan was dissolved in DMSO and quantified at 595 nm using
a microplate reader (Beckman-Coulter, Brea, CA).

Cholesterol visualization and quantification
TLC was employed to analyze the lipid profile in adipocytes.
Briefly, mature adipocytes (day 8) differentiated with or without
AVA (20 M) during days 4–8 were collected. Lipids were extracted via the Folch method. The extracted lipids were dissolved in chloroform/methanol (2:1 by volume), and 750 g
protein-related lipids were loaded in a small spot on a TLC silica
plate (MilliporeSigma, Burlington, MA). The mobile phase was
hexane:ether:acetic acid (80:20:1). Lipids were detected with iodine (29). The intensity of the iodine-stained lipids was quantified
using ImageJ software (The National Institutes of Health).
The intracellular cholesterol level was quantified by a cholesterol assay kit according to the manufacturer’s protocol. CE was
then calculated by subtracting the value of FC from the value of
total cholesterol. To visualize the cholesterol in adipocytes,
25-NBD-chol was employed. During adipogenesis (days 0–6), 3T3-L1
cells grown in a 96-well plate were subjected to 10% (v/v) FBS-DMEM
containing 25-NBD-chol (1 g/ml in DMSO) or DMSO control in
the presence or absence of AVA (20 M) for the indicated period
of time. After aspirating the medium and rinsing the cells with 1× PBS,
the fluorescence intensity in the cells was quantified using a microplate reader (SpectraMax Gemini EM, Molecular Devices, San
Jose, CA) at an excitation wavelength of 497 nm and an emission
wavelength of 551 nm. Additionally, 25-NBD-chol (1 g/ml) was
added to adipocytes (day 6) in the presence of AVA (20 M) or
DMSO control for 2 h. DNA-binding AT-specific fluorochrome
DAPI was used for nuclear staining. Fluorescent cell images
were obtained under confocal microscopy (Nikon A1R_MP, Nikon
Instruments, Inc., Melville, NY).

Multimodal coherent anti-Stokes Raman scattering
microscopy and stimulated Raman scattering imaging
Intracellular LDs in 3T3-L1 adipocytes were visualized by coherent anti-Stokes Raman scattering (CARS)-2-photon excitation
fluorescence analysis, as described previously (28). Briefly, the
CARS signal of TG in adipocytes was detected with the pump laser
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and Stokes laser set at 2,840 cm1. The CARS signal was then processed for visualization via an air condenser (numerical aperture,
0.55), a 600/65 nm band-pass filter, and a photomultiplier tube
(H7422-40; Hamamatsu, Japan). Deuterium-labeled glucose was
used to visualize and quantify de novo lipogenesis by stimulated
Raman scattering (SRS) imaging. The 3T3-L1 preadipocytes were
cultured in glass-bottomed dishes (#D35-10-1.5-N; Cellvis Inc.).
D-glucose (25 mM) in glucose-free DMEM supplemented with 10%
FBS-DMEM and 167 nM insulin was used to differentiate cells during days 2–4 with the indicated treatment. On day 4, cells were
washed with 1× PBS and fixed with 10% neutral buffered formalin
for 30 min, and then proceeded to SRS imaging, as described previously (30). Briefly, two femtosecond lasers produced from a
Ti:Sapphire laser (Chameleon Vision, Coherent) and an optical
parametric oscillator were used as pump and Stokes, respectively.
The pump wavelength was tuned to 830 nm. The Stokes beam
was tuned to 1,090 nm for imaging at a C-H vibration mode
around 2,850 cm1, and 1,005 nm for imaging at C-D vibration
mode around 2,120 cm1. A 40× water-immersion objective lens
(UplanSApo, Olympus) was used to focus the laser on the sample.
The acquisition time for an image with 512 × 512 pixels was 1.12 s.
SRS images were analyzed using ImageJ software. The lipid amount
was quantified using the threshold method in ImageJ.

Lentiviral shRNA-mediated knockdown of ACAT1 and
ACAT2
Plasmids encoding shRNA for mouse ACAT1 (TRCN0000197536;
Open Biosystems) and for mouse ACAT2 (SHCLNG-NM_146064,
TRCN0000246787; Sigma-Aldrich) were extracted with QIAGEN
HiSpeed Plasmid Midi kit. Lentivirus production was modified
from the standard protocol (31). The 293T cells and the third generation of lentivirus packaging plasmids were gifts from Dr. Timothy Ratliff’s laboratory, Purdue University. Briefly, 293T cells were
transfected with 10 g of the pLKO.1-target (pLKO.1-ACAT1,
pLKO.1-ACAT2, or pLKO.1-CTRL), 7.5 g of pMLDg/pRRE, 7.5
g of pRSV-rev, and 5 g of pVSV-g using Lipofectamine 2000.
After 16 h, fresh 10% FBS-DMEM was applied to the transfected cells and the virus medium was then collected 48 h later.
Virus particles were harvested by filtration (0.45 m pore size)
following centrifugation (40,000 g for 2 h). The harvested viruses

were employed to infect 3T3-L1 preadipocytes in the presence of
10 g/ml Polybrene to express ACAT1 or ACAT2 shRNA and
silence their target gene expression via RNA interference. Finally,
successfully transfected cells were selected by puromycin (1 g/ml)
and differentiated to adipocytes for various analyses. Gene knockdown efficiency was determined by real-time PCR assay.

Immunoblotting
The 3T3-L1 cells cultured in 6-well plates were harvested in cell
lysis buffer [50 mM Tris-HCl (pH 7.4), 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, protease inhibitor cocktail,
1 mM sodium orthovanadate, and 10 mM sodium fluoride]. These
samples were incubated in ice for 30 min and vortexed periodically.
After centrifugation at 18,000 g for 1 min, the supernatants were
transferred to new tubes for further analysis. The protein concentration was determined by Bradford assay (32) using the Bio-Rad protein assay. Fifty micrograms of protein with loading buffer were
loaded in each lane of a 7.5% SDS-PAGE gel and transferred to a
polyvinylidene difluoride membrane. Immunoblot was performed
with SREBP1 and -actin antibodies overnight at 4°C followed by
secondary HRP-conjugated rabbit and mouse antibodies, respectively. Pierce ECL Plus Western blotting reagents were applied to
develop the protein bands and ImageJ software was used to quantify
the band intensity. Band intensity of SREBP1 was normalized to the
band intensity of -actin in the same sample lane.

Real-time PCR analysis
Total RNA was extracted from various tissues or cells by TriZol
reagent. cDNAs were synthesized using SuperScript II reverse transcriptase and random primers according to the manufacturer’s
protocol. Real-time PCR with iTaq™ Universal SYBR® Green Supermix was used to quantify gene expression by StepOne realtime PCR system (Applied Biosystems). The primer sequences
are listed in Table 1. Data was normalized to -actin or ribosomal
protein L27 (RPL27, an 18S ribosomal protein), as indicated,
and analyzed using the Ct method.

Statistical analysis
Data are presented as mean ± SEM. Statistical analysis was performed using the Student’s two-tailed t-test to compare between

TABLE 1. Primer sequences used for real-time PCR
Primer Sequence (5′-3′)
Genes

ACAT1
ACAT2
UCP1
Leptin
SREBP1
PPARr
FAS
SCD1
MGAT1
DGAT1
DGAT2
Adipoq
Resistin
SR-BI
CD36
ABCA1
ABCG1
SREBP1a
SREBP1c
SREBP2
-Actin
RPL27

Forward

Reverse

TCGCACTCCTCATCCTATTCG
AGACTTGGTGCAATGGACTCGAC
TCATCATCAATTGTACAGAGCTGGTA
CACACACGCAGTCGGTATCC
GGCACTGAAGCAAAGCTGAAT
CCCAATGGTTGCTGATTACAAAT
ACCACTGCATTGACGGCCGG
GGTGATGTTCCAGAGGAGGTACTAC
CTGGTTCTGTTTCCCGTTGT
GTGCACAAGTGGTGCATCAG
GCCGTGTGGCGCTACTTC
GGAACTTGTGCAGGTTGGAT
TGCCAGTGTGCAAGGATAGACT
GGCTGCTGTTTGCTGCG
GTTCTTCCAGCCAATGCCTTT
GGTTTGGAGATGGTTATACAATAGTTGT
AGGTCTCAGCCTTCTAAAGTTCCTC
AGATGTGCGAACTGGACACA
GGAGCCATGGATTGCACATT
TGTGAACCTGGCCGAGTGT
AGATGACCCAGATCATGTTTGAGA
CCTGGCCGGACGCTACT

GTACCAGCCTTCCTTCATCGAT
CATAGGGCCCGATCCAACAG
CGTCATCTGCCAGTATTTTGTTG
AGCCCAGGAATGAAGTCCAA
GCAAGAAGCGGATGTAGTCGAT
CTACTTTGATCGCACTTTGGTATTCT
GGGTCAGGCGGGAGACCGAT
AGCGTGGGCAGGATGAAG
TGGGTCAAGGCCATCTTAAC
CAGTGGGATCTGAGCCATCA
GTGGTCAGCAGGTTGTGTGTCT
GCTTCTCCAGGCTCTCCTTT
CGCTCACTTCCCCGACAT
GCTGCTTGATGAGGGAGGG
ATGTCTAGCACACCATAAGATGTACAGTT
TTCCCGGAAACGCAAGTC
TCTCTCGAAGTGAATGAAATTTATCG
CATCTTTAAAGCAGCGGGTG
CATCTTTAAAGCAGCGGGTG
CGCTGTCAGGTGGATCTCAA
CACAGCCTGGATGGCTACGT
AGGTGCCATCGTCAATGTTCT

UCP1, uncoupling protein 1.
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groups. One-way ANOVA with Bonferroni post hoc test was
performed to analyze the data generated in Figs. 1D, 1E, 3A, and
supplemental Fig. S1 with SAS 9.2 (SAS® Institute Inc., Cary, NC).
P < 0.05 was considered statistically significant.

RESULTS
ACAT inhibition suppresses lipid accumulation in
adipocytes
We first examined the expression patterns of ACAT1
and ACAT2 in adipose tissue from lean and diet-induced
obese (DIO) mice. ACAT1 mRNA expression was higher
(2.2-fold) while ACAT2 was lower (0.4-fold) in epididymal white adipose tissue (epiWAT) isolated from DIO
mice compared with that in age-matched lean mice (Fig.
1A). On the other hand, brown adipose tissue (BAT) from
DIO mice had higher mRNA levels of both ACAT1 (1.9fold) and ACAT2 (2.8-fold) compared with those in agematched lean mice (Fig. 1B). These results imply a positive
correlation between adipose ACAT1 expression and adiposity in vivo. Next, to determine the role of ACATs in adipocyte function, we examined the mRNA levels of ACAT1
and ACAT2 during adipogenesis of 3T3-L1 murine preadipocytes. While the mRNA level of ACAT1 increased 2.2fold during adipogenesis (Fig. 1C), the ACAT2 mRNA
level markedly decreased during the early stage of adipogenesis (Fig. 1C), indicating a positive correlation between
ACAT1 expression and adipocyte differentiation in vitro. To
further understand the role of ACAT in adipogenesis, we
next examined the effect of ACAT inhibition on adipogenesis using AVA (CI-1011), a clinically proven ACAT inhibitor
(33). AVA suppressed lipid accumulation in differentiating
3T3-L1 preadipocytes in a dose-dependent manner, with a
maximum decrease of 70% at 20 M AVA, as judged by
ORO staining (Fig. 1D). AVA showed little effect on cell
viability (Fig. 1E). Consistently, another ACAT inhibitor,
CI-976 (34), also blocked lipid accumulation in 3T3-L1 adipocytes (supplemental Fig. S1A) with an undetectable effect
on cell viability (supplemental Fig. S1B). Supporting this
result, CARS microscopy revealed AVA-induced reduction
of LD size and number during adipogenesis (Fig. 1F).
As the majority of lipids found in LDs in adipocytes are
TG (3), we tested to determine whether AVA altered adipocyte TG content. Lipids extracted from AVA-treated adipocytes contained about 45% less TG than controls (Fig.
1G), as assessed by TLC. These results suggest that AVAinhibited lipid accumulation was largely attributed to reduced TG content in adipocyte LDs. AVA treatment also
resulted in an approximately 57–96% reduction in mRNA
levels of genes involved in the adipogenic transcription
program (e.g., PPAR and SREBP1) (Fig. 1H), lipid synthesis [e.g., FAS, stearoyl-CoA desaturase-1 (SCD1), acylCoA:monoacylglycerol acyltransferase (MGAT)1, and DGAT2]
(Fig. 1I), and adipokine production (e.g., adiponectin,
leptin, and resistin) (Fig. 1J) compared with those in the
control group. Taken together, our results indicate that
inhibiting ACAT activity suppresses LD formation and
adipogenesis in vitro.

ACAT inhibition alters intracellular cholesterol balance
in adipocytes
To understand the impact of ACATs on intracellular adipocyte cholesterol levels, we examined the effect of ACAT
inhibition on FC and CE levels during adipogenesis. Consistent with a previous study (23), we observed that adipogenesis was associated with an increase in intracellular FC
level in 3T3-L1 adipocytes (Fig. 2A). Notably, AVA treatment during adipogenesis significantly suppressed the intracellular levels of FC (Fig. 2A) and CE (supplemental Fig.
S2) in adipocytes.
As cholesterol in adipocytes is largely associated with cellular membranes and LDs and ACATs play a role in cholesterol absorption and intracellular cholesterol homeostasis
in nonadipocytes (35, 36), we examined the effect of AVA
treatment on incorporation of 25-NBD-chol, a fluorescent
cholesterol analog (37), in adipocytes. We found that both
2 h and 48 h of AVA treatment in mature adipocytes suppressed incorporation of 25-NBD-chol in adipocytes
(Fig. 2B, C). However, AVA treatment showed no effect on
25-NBD-chol incorporation in differentiating adipocytes
when treated during the early stage of adipogenesis (i.e.,
days 0–2) (data not shown). Moreover, AVA treatment in
adipocytes during the late stage of adipogenesis resulted
in a marked reduction of mRNA levels of genes involved
in cholesterol uptake [scavenger receptor class BI (SR-BI)
and CD36] as well as genes in cholesterol efflux (ABCA1
and ABCG1) by 53–94% (Fig. 2D). Taken together, we
demonstrate that ACAT inhibition effectively lowered intracellular cholesterol levels in differentiated adipocytes by
altering both cholesterol uptake and possibly cholesterol
efflux.
ACAT inhibition reduced lipogenic gene expression in
adipogenesis through inhibition of SREBP1 processing
To understand the molecular basis underlying the inhibitory effect of ACAT inhibition on LD formation in adipocytes, we first attempted to identify the critical stage of
adipogenesis that is specifically targeted by ACAT inhibition in adipocytes. Differentiating 3T3-L1 cells exposed to
the adipogenic cocktail were treated with 20 M AVA at
various time points, as illustrated in Fig. 3A. As shown in
Fig. 3A, adipocytes incubated with AVA during days 0–2
had similar levels of lipid accumulation as control adipocytes. However, adipocytes treated with AVA during days
2–4, days 2–6, or days 4–6 exhibited more than 50% reduction in intracellular lipid content compared with control
adipocytes (Fig. 3A). As expected, adipocytes treated with
AVA during days 2–4 displayed reduced mRNA levels of
genes involved in lipogenesis (PPAR, SREBP1a, SREBP1c,
and SREBP2) by 57–99% and TG synthesis (MGAT1, DGAT1,
and DGAT2) by more than 95% (Fig. 3B, C).
Given the role of SREBPs in the regulation of genes
in cholesterol synthesis and uptake, FA synthesis, and TG
homeostasis (38), we hypothesized that ACAT inhibition
would impair SREBP-regulated de novo lipogenesis. To
test this hypothesis, we first investigated the effect of AVA
on SREBP1 processing in adipocytes. Compared with nontreated adipocytes, AVA reduced SREBP1 cleavage by 70%
ACATs and lipid droplet formation

823

Fig. 1. Inhibiting ACATs suppresses lipid accumulation in adipocytes during adipogenesis. A, B: mRNA levels of ACAT1 and ACAT2 determined by real-time PCR in epiWAT (A) and BAT (B) from chow diet-fed mice and age-matched DIO mice (male, 13 weeks old, C57BL/6J,
Jackson Laboratory). Signals were normalized to RPL27 (n = 4). C: mRNA levels of ACAT1 and ACAT2 in 3T3-L1 cells during adipogenesis
as determined by real-time PCR and normalized to -actin (n = 3, repeated three times). D: ORO staining from adipocytes (day 6) that were
differentiated with or without AVA at various concentrations (1–20 M) for 6 days (n = 3). E: Adipocyte viability upon AVA treatment (0–20 M)
for 48 h was determined by MTT assay (n = 3). F: CARS image analysis of intracellular LDs in adipocytes that were differentiated in the
presence or absence of AVA (10 or 20 M) for 9 days (n = 3). G: Mature adipocytes differentiated with or without AVA (20 M) during days
4–8 were subjected to TLC. The intensity of the TG spots in TLC was quantified by ImageJ and normalized to control (CTRL) (n = 3). mRNA
levels of genes involved in adipogenic transcription program (H), lipid synthesis (I), and adipokine production (J) were determined by realtime PCR with signals normalized -actin (n = 3). All the data were normalized to control. Data presented are expressed as mean ± SEM.
Student’s two-tailed t-test was applied to A–C and G–J. *P < 0.05; **P < 0.01; ***P < 0.001. One-way ANOVA with Bonferroni post hoc test was
applied in D and E, and different lowercase letters indicate significant different (P < 0.05).
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Fig. 2. ACAT inhibition alters the intracellular cholesterol balance in adipocytes. A: The 3T3-L1 preadipocytes were differentiated in the presence or absence
of 20 M AVA for 6 days and the cells were harvested
at various stages of adipogenesis as indicated [day
(D)0, D2, D4, and D6] for measurement of FC level
(n = 3). B: The 3T3-L1 adipocytes (D6) treated with a
fluorescent cholesterol analog (25-NBD-chol, 1 g/ml)
and DAPI in the presence or absence of AVA (20 M)
for 2 h. Representative images by confocal microscopy
are presented (n = 3). C: The 3T3-L1 cells (day 2) were
cultured in medium supplemented with or without
AVA (20 M) or 25-NBD-chol (1 g/ml) for 48 h, and
then the intracellular fluorescence intensity was quantified (n = 5). Data were normalized to DMSO-treated
control. D: mRNA levels of genes involved in cholesterol uptake (SR-BI and CD36) and cholesterol efflux
(ABCA1 and ABCG1) were determined by real-time
PCR and normalized to -actin (n = 3). Data presented
are the mean ± SEM; *P < 0.05; **P < 0.01; ***P < 0.001.

(Fig. 3D). Consequently, AVA treatment reduced mRNA
expression of SREBP1 downstream genes, such as FAS
and SCD1, by approximately 96% (Fig. 3E). Additionally,
we employed noninvasive SRS microscopy coupled with
deuterium-labeled glucose to trace the impact of AVA
on de novo lipogenesis in adipocytes (30). This method
allowed us to visualize and quantify de novo lipogenesis in
LDs as indicated by the C-H bond vibration from existing
lipids, and the C-D bond vibration from newly synthesized
deuterium-containing lipids. Accordingly, the ratio of the
C-D signal over C-H signal indicates the level of de novo lipogenesis. AVA treatment suppressed both LD formation and
deuterium-labeled FA production, which effectively lowered
de novo lipogenesis by 7.4% (Fig. 3F). Taken together, we
found that ACAT inhibition suppressed TG accumulation
in adipocytes mainly through reducing de novo lipogenesis
in vitro, and in part by abrogating SREBP1 maturation and
expression of its downstream lipogenic genes.
ACATs are required for lipid accumulation in adipocytes
In order to verify the role of ACAT in LD development
in adipocytes, we stably knocked down ACAT1 in 3T3-L1
preadipocytes. Knockdown efficiency was 80%, as determined by real-time PCR (Fig. 4A). ACAT1 knockdown
slightly increased ACAT2 expression (Fig. 4A), with no effect
on DGAT1 and DGAT2 levels (supplemental Fig. S3). After
6 days of differentiation, shACAT adipocytes accumulated

40% less lipids that shCTRL adipocytes (Fig. 4B) and displayed reduced expression of PPAR and SREBP1 and its
downstream genes, FAS and DGAT2 (Fig. 4C). To test the
requirement of ACAT2 for LD generation in adipocytes,
we stably silenced ACAT2 in 3T3-L1 preadipocytes. This resulted in 80% suppression of ACAT2 expression (Fig. 4D).
ACAT2 knockdown slightly increased ACAT1 level (Fig. 4D),
but showed no effect on DGAT1 and DGAT2 levels (supplemental Fig. S3). After 6 days of differentiation, shACAT2
adipocytes contained 55% less lipids than the shCTRL adipocytes (Fig. 4E). Consistently, ACAT2 knockdown dramatically reduced mRNA levels of genes involved in TG synthesis
(PPAR, SREBP1, FAS, and SCD1) (Fig. 4F). We also observed a decrease of ACAT1 mRNA level in differentiated
shACAT2 adipocytes (Fig. 4F). Collectively, these results
implicate that both ACAT genes are required for LD development in adipocytes in vitro.

DISCUSSION
Adipose tissue is a major cholesterol storage organ (1),
and its intracellular cholesterol level is positively correlated
with an increase in fat cell size and TG level in adipocytes
(3–5). Although FC and CE appear to play an important
role in TG synthesis and LD formation, at least in hepatocytes (39) and Saccharomyces cerevisiae (19), the role of
ACATs and lipid droplet formation

825

Fig. 3. ACAT inhibition reduces lipogenic gene expression in adipogenesis through inhibition of SREBP1 processing. A: The 3T3-L1
preadipocytes were differentiated with or without AVA (20 M) for the indicated period of time. After 6 days of differentiation, ORO staining was performed and the corresponding quantification was calculated to determine the intracellular lipid content. Representative images
are presented (n = 3). The 3T3-L1 cells were cocultured with or without AVA (20 M) for 48 h from day 2 and were harvested to determine
mRNA levels of PPAR, SREBP1a, SREBP1c, and SREBP2 (B) and MGAT1, DGAT1, and DGAT2 (C) (n = 3). Adipocytes differentiated in the
presence or absence of AVA (10 M, during days 2–6) were subjected to immunoblotting to determine SREBP1 level (D) and real-time PCR
to determine the mRNA levels of SREBP1 downstream genes (E) (n = 3). F: During adipogenesis, 3T3-L1 cells (day 2) were cultured in
medium supplemented with deuterium-glucose (D-Glucose) (25 mM) in the presence or absence of AVA (10 M) for 2 days. SRS imaging
was taken at the carbon-deuterium (C-D) vibration (2,120 cm1) and the carbon-hydrogen (C-H) vibration (2,850 cm1), indicating
total lipids and deuterium-incorporated lipids, respectively. ImageJ was used for quantification (n = 3). Data are presented are mean ± SEM.
One-way ANOVA with Bonferroni post hoc test was applied to A, and different lowercase letters indicate significant different (P < 0.05).
Student’s two-tailed t-test was applied to B–F. *P < 0.05; **P < 0.01; ***P < 0.001.
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Fig. 4. ACAT1 or ACAT2 are required for lipid accumulation. A: Preadipocytes were infected with lentiviral particles carrying either an
ACAT1-targeted shRNA (shACAT1) or a scrambled shRNA (shCTRL). mRNA levels of ACAT1 and ACAT2 in ACAT1 knockdown (shACAT1)
or control (shCTRL) preadipocytes were measured by real-time PCR (n = 3) to determine the knockdown specificity and efficacy. B: shCTRL
and shACAT1 preadipocytes were differentiated to mature adipocytes for 6 days and then stained with ORO to quantify lipid content (n = 3).
Representative images are shown. C: Mature adipocytes differentiated from shCTRL and shACAT1 preadipocytes were subjected to real-time
PCR to determine the mRNA levels of genes involved in adipogenesis, lipid synthesis, and adipokine production (n = 3). D: mRNA levels of
ACAT1 and ACAT2 in ACAT2 knockdown (shACAT2) or control (shCTRL) preadipocytes were measured by real-time PCR (n = 3) to determine the knockdown specificity and efficacy. E: shCTRL and shACAT2 preadipocytes were differentiated to mature adipocytes for 6 days and
then stained with ORO to quantify lipid content (n = 3). Representative images are shown. F: Mature adipocytes differentiated from shCTRL
and shACAT2 preadipocytes were subjected to real-time PCR to determine mRNA levels of genes involved in adipogenesis and lipid synthesis
(n = 3). Data presented are the mean ± SEM and analyzed by Student’s two-tailed t-test. *P < 0.05; **P < 0.01; ***P < 0.001.
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ACAT in LD formation in adipocytes remains poorly
understood.
Herein, we demonstrated that ACATs are required to
maintain intracellular TG and cholesterol levels during
adipogenesis. This inhibitory effect of ACATs was, at least
in part, mediated by suppressing SREBP1-dependent de
novo lipogenesis. Our finding is in agreement with the previous studies of a role of ACAT in TG synthesis in other cell
types. In HepG2 cells, pharmacological inhibition of ACAT
lowered the synthesis of TG, cholesterol, and CE (40). In
obese patients, higher ACAT activity correlated with increased lipid levels in the liver (41). Conversely, silencing
ARE1 (the yeast homolog of mammalian ACAT1) in yeast
lowered the TG level without changing cholesterol levels
(42). We speculate that the effect of ACAT on TG level is
partly through modulation of the SREBP1 pathway, as evidenced by AVA-inhibited SREBP1 maturation and expression of SREBP1 target genes. It has been well-established
that SREBP1-regulated lipogenesis is largely controlled by
the intracellular cholesterol pool of FC and CE (43), reflecting a balance between uptake, efflux, and de novo synthesis. Our study shows that ACAT inhibition resulted in a
decrease in intracellular FC level, and FC uptake and efflux
in differentiating adipocytes. We also found a decreased
intracellular CE level in differentiating adipocytes when
treated with AVA (supplemental Fig. S2). These results indicate that ACAT inhibition suppresses the overall intracellular cholesterol pool of FC and CE in adipocytes. Our
study is supported by the previously reported role of ACAT
in modulating the intracellular cholesterol pool in various
cell types: In macrophages (44) and in bone metastasisderived PC-3 cells (15), ACAT inhibition resulted in increased intracellular FC levels and decreased intracellular
CE levels. In neurons, however, blocking ACAT1 activity
suppressed CE synthesis without changing intracellular FC
levels (16). Locally, CE is formed on the ER membrane
where it modulates the function of ER resident ACATs and
SREBP1 (38). Thus, it is plausible that our finding of AVAinhibited SREBP1 function and TG synthesis is likely to be
attributed to both an altered local cholesterol balance on
the ER membrane and a decreased intracellular cholesterol pool in adipocytes.
There is increasing evidence that cholesterol uptake and
efflux are associated with changes in energy metabolism
and function of adipocytes. Enhanced cholesterol uptake
by upregulating oxidized low density lipoprotein receptor 1 improved FA uptake in adipocytes (45). Additionally,
blocking cholesterol transport by NPC2 knockdown impaired
autophagy-related mitochondrial function and blunted
lipopolysaccharide-stimulated inflammation in adipocytes
(46). Moreover, adipocyte-specific ABCA1-deficient mice
with impaired cholesterol export displayed reduced lipogenesis, adipocyte lipid storage and adiposity, and increased
systemic energy expenditure, thereby impairing diet-induced
obesity in vivo (26). In contrast, alteration of cholesterol
efflux in epiWAT by administration of ABCG1 shRNA
resulted in lowering cellular cholesterol, inflammation, and
fat storage (47). Our study identified ACAT as an important
regulator in the existing paradigm concerning the role
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of the intracellular cholesterol pool in the lipogenic ability
of adipocytes. Additional work is needed to determine the
physiological consequence of the ACAT-regulated intracellular cholesterol pool in adipose tissue to systemic energy
balance and metabolism in vivo.
In summary, our study demonstrates that ACAT plays a
critical role in regulating the cholesterol and TG storage
ability of adipocytes in that ACAT inhibition and ACAT deficiency resulted in suppression of lipogenesis and the intracellular cholesterol pool. These results highlight an
important role of ACAT in linking cholesterol metabolism
to TG synthesis in adipocytes.
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